Table 2

Characteristics of patients who sustained or did not sustain remission for 1 year after fulfilling the ADA-free criteria

Measurement itemsSustained remission (n=25)Failed remission (n=27)p Value
Age (years)57.1±13.262.6±8.90.0833
Disease duration (years)6.6±8.49.8±11.10.0488*
ADA admin periods (weeks)59.8±23.775.6±30.00.0264*
ESR (mm/h)11.2±6.320.2±11.40.0019**
CRP (mg/dL)0.09±0.150.11±0.220.3289
RF (U/mL)58.6±67.330.9±34.70.2096
MMP-3 (mg/mL)56.0±25.049.3±31.40.1129
MTX (mg/w)8.1±2.58.6±2.00.7645
  • Data are reported as means± SD, unless otherwise indicated. Statistical significance was assessed by the Wilcoxon rank sum test. *p<0.05, **p<0.01: sustained remission versus failed remission.

  • ADA administration periods, adalimumab administration periods; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28, disease activity score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; mTSS, modified total sharp score; RF, rheumatoid factor; SDAI, simplified disease activity index.